Incyte Reports Positive Phase 3 frontMIND Results Showing Tafasitamab and Lenalidomide Plus R-CHOP Improves Outcomes in High-Risk DLBCL and HGBL
Incyte has announced positive results from its pivotal Phase 3 frontMIND clinical trial, demonstrating that the addition of tafasitamab and lenalidomide to the standard R-CHOP regimen significantly improved outcomes for patients with newly diagnosed high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The findings were presented during a prestigious Plenary Abstract Session at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden, and were also recently published in the medical journal The Lancet.
The study represents one of the most important advances in frontline treatment for aggressive B-cell lymphomas in recent years. For decades, R-CHOP—a combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone—has remained the standard first-line treatment for DLBCL. While the regimen has cured many patients, outcomes have remained suboptimal for individuals with high-risk disease, creating an urgent need for more effective treatment approaches.
The frontMIND trial evaluated whether adding tafasitamab, a humanized Fc-modified CD19-targeting monoclonal antibody, together with lenalidomide, could enhance the effectiveness of R-CHOP and reduce the likelihood of disease progression or relapse in patients with aggressive lymphoma.
Addressing an Unmet Need in High-Risk Lymphoma
Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma and is characterized by rapidly growing malignant B cells. Although many patients respond well to frontline therapy, those classified as high risk based on prognostic scoring systems often experience poorer outcomes and a greater chance of relapse.
The frontMIND study specifically enrolled adults with previously untreated DLBCL or HGBL who were considered at elevated risk for treatment failure. Eligible participants had an International Prognostic Index (IPI) score of 3 to 5 or, for younger patients aged 60 years or below, an age-adjusted IPI score of 2 to 3.
By focusing on this challenging patient population, researchers aimed to determine whether an intensified immunotherapy-based strategy could improve long-term disease control beyond what has been achieved with standard therapy alone.
According to Steven Stein, M.D., Executive Vice President, Chief Medical Officer, and Head of Late-Stage Development at Incyte, the results provide compelling evidence that the combination regimen may redefine frontline treatment for patients with high-risk disease.
Stein noted that outcomes for high-risk DLBCL and HGBL have remained largely unchanged for decades, making the positive findings particularly significant. He emphasized that the benefits observed across multiple predefined patient subgroups suggest the therapy could potentially become a new standard of care if approved by regulatory authorities.
Significant Improvement in Progression-Free Survival
The primary endpoint of the frontMIND trial was progression-free survival (PFS), a critical measure assessing how long patients remain alive without disease progression.
Results showed that the combination of tafasitamab, lenalidomide, and R-CHOP significantly reduced the risk of disease progression or death compared with R-CHOP alone.
Researchers reported a 25% reduction in the risk of progression or death among patients receiving the experimental regimen. The hazard ratio was 0.75, representing a statistically significant improvement over the standard treatment arm.
At two years, progression-free survival reached 71.1% in patients treated with the tafasitamab-based regimen compared with 62.9% in those receiving standard R-CHOP alone. This translated into an absolute improvement of 8.2 percentage points.
The benefit remained durable over time. At three years, progression-free survival was 67.3% in the experimental arm versus 60.7% in the control group, representing a 6.6 percentage-point advantage.
These findings suggest that the addition of tafasitamab and lenalidomide may help prevent disease recurrence and provide longer-lasting disease control for patients at high risk of relapse.
Benefits Observed Across Multiple Patient Subgroups
One of the notable aspects of the study was the consistency of benefit observed across a broad range of predefined patient populations.
Investigators reported that trends favoring the tafasitamab-containing regimen were generally consistent regardless of lymphoma subtype or molecular classification.
This included patients whose diagnoses were centrally confirmed as DLBCL or HGBL and those representing different cell-of-origin molecular subtypes.
Historically, molecular subtypes such as activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL have demonstrated varying responses to different therapies. The observation that benefit was seen across both groups suggests the treatment may have broad applicability in frontline lymphoma management.
Such consistency strengthens confidence that the combination could benefit a wide spectrum of high-risk patients rather than only a narrowly defined subgroup.
Improvements Beyond the Primary Endpoint
In addition to progression-free survival, the study demonstrated improvements across several important secondary endpoints.
Event-free survival (EFS), which measures the time until disease progression, relapse, treatment failure, or death, was significantly improved among patients receiving tafasitamab and lenalidomide alongside R-CHOP.
The combination achieved a statistically significant reduction in the risk of experiencing an event compared with standard therapy.
Investigators also reported encouraging findings regarding minimal residual disease (MRD), a sensitive measure used to detect small numbers of remaining cancer cells after treatment.
MRD negativity rates were substantially higher in the tafasitamab-containing treatment arm. Approximately 81.3% of patients receiving the combination achieved MRD negativity compared with 66.7% of patients treated with R-CHOP alone.
Achieving MRD negativity is often associated with deeper treatment responses and improved long-term outcomes, making this finding particularly encouraging.
The study also included an interim analysis of overall survival (OS). While the results did not yet reach statistical significance, a positive trend favoring the experimental regimen was observed.
Researchers reported fewer overall deaths in the tafasitamab treatment arm than in the control group, suggesting that the progression-free survival benefit may eventually translate into a survival advantage with longer follow-up.
Preventing Relapse Remains a Critical Goal
Dr. Georg Lenz of University Hospital Münster, the principal investigator of the frontMIND trial, highlighted the clinical importance of preventing relapse in frontline lymphoma treatment.
He explained that one of the primary objectives when treating newly diagnosed patients is to maximize the likelihood of cure and reduce the need for additional therapies later in the disease course.
This goal is particularly important for individuals with high-risk DLBCL and HGBL, where relapse often leads to more intensive treatments, including stem cell transplantation or cellular therapies.
According to Lenz, the frontMIND results are especially encouraging because the addition of tafasitamab and lenalidomide improved clinical outcomes without compromising the delivery of the R-CHOP backbone, which remains a foundational component of lymphoma treatment.
Maintaining the integrity of standard chemotherapy while enhancing efficacy is considered an important advantage for any frontline treatment strategy.
Safety Profile Remains Manageable
The safety analysis showed that the combination regimen was generally well tolerated and consistent with expectations based on the known safety profiles of tafasitamab, lenalidomide, and R-CHOP.
Nearly all patients in both treatment groups experienced at least one treatment-emergent adverse event, reflecting the intensive nature of lymphoma therapy.
The most frequently reported adverse events among patients receiving tafasitamab, lenalidomide, and R-CHOP included neutropenia, anemia, and peripheral neuropathy.
Severe adverse events of Grade 3 or higher occurred more frequently in the experimental arm than in the standard treatment arm. However, investigators reported that these events were generally manageable and did not interfere with the administration of the underlying R-CHOP regimen.
Among the most common severe adverse events in the combination group were anemia, thrombocytopenia, and neutropenia.
Importantly, treatment discontinuation rates were nearly identical between the two groups, suggesting that the addition of tafasitamab and lenalidomide did not substantially reduce treatment tolerability.
Although the experimental arm showed a slightly higher rate of fatal treatment-emergent adverse events, researchers observed fewer overall deaths among patients receiving the combination regimen than among those receiving standard therapy alone. This finding aligns with the favorable trend seen in overall survival analyses.
Potential to Establish a New Standard of Care
The frontMIND trial represents a significant milestone in the development of tafasitamab and lenalidomide as components of frontline lymphoma treatment.
Tafasitamab is already approved in several regions for specific relapsed or refractory DLBCL settings, and the positive Phase 3 data now support expanding its use into the first-line treatment setting.
If approved, the combination could become one of the first major advances to improve outcomes beyond standard R-CHOP in a broad population of newly diagnosed high-risk DLBCL and HGBL patients.
The study’s findings are particularly noteworthy because they demonstrate improvements in progression-free survival, event-free survival, and minimal residual disease negativity while maintaining a manageable safety profile.
Regulatory Plans and Future Outlook
The positive results from frontMIND are expected to form the basis of global regulatory submissions seeking approval of tafasitamab and lenalidomide in combination with R-CHOP for patients with previously untreated DLBCL and HGBL.
Regulatory authorities will review the comprehensive clinical data package to determine whether the combination should become available as a new frontline treatment option.
For patients diagnosed with aggressive high-risk lymphoma, the prospect of a therapy capable of reducing relapse risk and improving long-term disease control represents a potentially transformative development.
As additional follow-up data become available, investigators will continue monitoring overall survival outcomes and long-term safety. However, the current findings already suggest that combining tafasitamab and lenalidomide with R-CHOP could significantly reshape the treatment landscape for high-risk DLBCL and HGBL, offering new hope to patients facing these aggressive blood cancers.
About DLBCL
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in adults worldwide, representing 40% of all cases.1 It is characterized as an aggressive, fast-growing type of lymphoma that can emerge in lymph nodes or extranodal sites such as the gastrointestinal tract, skin and brain.2 Each year, approximately 24,000 people in the U.S. and up to 36,000 people in Europe are diagnosed with DLBCL.3,4 With about 40% of these patients not responding to initial therapy or relapsing thereafter5,6, there is a high medical need for new, effective therapies, particularly for high-risk patients.
About frontMIND
The frontMIND trial (NCT04824092) is a randomized, double-blind, placebo-controlled, global Phase 3 study in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL).
The study enrolled 899 adults (≥18 to ≤80 years) and is evaluating the efficacy and safety of tafasitamab and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared with R-CHOP.
The primary endpoint of the study is investigator-assessed progression-free survival (PFS) using the Lugano 2014 criteria. Key secondary endpoints include event-free survival (EFS) by investigator assessment and overall survival (OS).
About Tafasitamab (Monjuvi®/Minjuvi®)
Tafasitamab (Monjuvi®/Minjuvi®) is a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.
In the U.S., Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). Additionally, Monjuvi received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Monjuvi is not indicated and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.
In Europe, Minjuvi® (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. In addition, in December 2025, the EMA approved Minjuvi, in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory FL (Grade 1-3a) after at least one line of systemic therapy.
